<DOC>
	<DOCNO>NCT02992964</DOCNO>
	<brief_summary>This open-label , single arm , multi-center , pilot study Nivolumab pediatric patient recurrent refractory hypermutant malignancy age 12 month 18 year age . This study assess clinical radiological benefit treatment Nivolumab child hypermutated cancer , include bMMRD syndrome . It expectation patient bMMRD syndrome account majority patient enrol study .</brief_summary>
	<brief_title>Pilot Study Nivolumab Pediatric Patients With Hypermutant Cancers</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplastic Syndromes , Hereditary</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must ≥ 12 month &lt; 18 year age time study enrollment . 2 . Patients must histologic verification malignancy time diagnosis and/or relapse . 3 . Patients must recurrent refractory tumour . All tumour type eligible ( include malignant hematological condition ) , long criteria met . 4 . Patients must evidence biallelic mismatch repair deficiency either tumour tissue ( immunohistochemistry sequence ) germline ( sequence ) and/or evidence hypermutant malignancy whole exome sequence mutation load &gt; 100 per exome . 5 . Patients must either measurable evaluable disease . 6 . Patients multiple concurrent sequential neoplasm ( e.g . glioblastoma colon cancer ) eligible . 7 . Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life.. 8 . Karnofsky ≥ 50 % patient &gt; 16 year age Lansky ≥ 60 patient ≤ 16 year age ( See Appendix I KarnofskyLansky Scores ) . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . 9 . Patients must fully recover acute toxic effect prior anticancer therapy : Myelosuppressive Chemotherapy : least 21 day last dose myelosuppressive chemotherapy ( 42 day prior Nitrosourea ) . Hematopoietic Growth Factors : At least 14 day last dose longacting growth factor ( e.g . Neulasta ) 7 day shortacting growth factor . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study sponsor . Biologic ( Antineoplastic Agent ) : least 14 day last dose biologic agent . For agent know adverse event occur beyond 14 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study sponsor . Monoclonal Antibodies : least 3 halflives antibody last dose monoclonal antibody . XRT : least 14 day local palliative XRT ( small port ) ; At least 150 day must elapse prior Total Body Irradiation ( TBI ) , craniospinal XRT ≥ 50 % radiation pelvis ; At least 42 day must elapse substantial BM radiation . Stem Cell Infusion without TBI : evidence active graft vs. host disease least 56 day must elapse transplant stem cell infusion . Patients prior allogeneic transplant eligible . 10 . Patients must receive prior exposure antiPD1 orantiPDL1 agent 11 . Organ Function Requirements 1 . Adequate Bone Marrow Function Defined : For patient solid tumour without know bone marrow involvement : Peripheral absolute neutrophil count ( ANC ) ≥ 0.75 x 109/L 750/mm3 , Platelet count ≥ 75 x 109/L 75,000/mm3 , Hgb ≥ 90 g/L ( transfusion independent , define receive platelet and/or red blood cell transfusion least 7 day prior enrollment ) Patients known bone marrow metastatic disease eligible study provide meet haematological criterion ; patient may receive transfusion provide known refractory red blood cell platelet transfusion . These patient evaluable hematologic toxicity . 2 . Adequate Renal Function Defined : A serum creatinine base age/gender follow : Age Maximum Serum Creatinine ( mg/dL ) Male Female 1 &lt; 2 year 0.6 0.6 2 &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 Table 4 . The threshold creatinine value Table derive Schwartz formula ( Schwartz Gauthier 1985 ) estimate GFR utilize child length stature data publish CDC . 3 . Adequate Liver Function Defined : • Bilirubin ( sum conjugate + unconjugated ) ≤ 1.5 x upper limit normal ( ULN ) age ( except patient Gilbert Syndrome , must total bilirubin less 51 µmol/L 3.0 mg/dL ) . • ALT/AST ≤ 2.5 ULN patient without liver metastasis ≤ 5 x ULN patient liver metastasis For purpose study , ULN ALT 45 U/L , AST 52 U/L . 4 . Adequate Pulmonary Function Defined : No history chronic pulmonary disease ( Cystic Fibrosis ) evidence dyspnea rest , exercise intolerance due pulmonary insufficiency pulse oximetry &gt; 92 % room air . 5 . Adequate Pancreatic Function Defined : Serum lipase ≤ ULN . Patients glucose intolerance stable regimen monitor . 3 . Pregnancy BreastFeeding Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event yet available information regard human fetal teratogenic toxicity . Women childbearing potential ( WOCBP ) * must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 1 week prior start Nivolumab . WOCBP sexually active must willing adhere effective contraception** treatment 23 week last dose Nivolumab . Men sexually active WOCBP must willing adhere effective contraception** treatment 31 week last dose study drug . Women , surgically sterile well azoospermic men require contraception . `` Women childbearing potential '' define female experience menarche undergone surgical sterilization ( hysterectomy bilateral oophorectomy ) postmenopausal . List contraception method provide Appendix II 4 . Concomitant Medications Corticosteroids : Patients require daily systemic immunosuppressive dose corticosteroid ( &gt; 2mg/kg/day prednisone equivalent ) eligible . Patients must receive systemic corticosteroid within 7 day prior enrollment . Note : Use topical , ocular , intraarticular , intranasal inhale corticosteroid render patient ineligible . Physiological replacement dos systemic steroid permit even &gt; 10mg/day prednisone equivalent . A brief course corticosteroid prophylaxis ( eg , contrast dye allergy ) treatment nonautoimmune condition ( eg , delayedtype hypersensitivity reaction cause contact allergen ) permit complete least 7 day prior initiation therapy . Investigational Drugs : Patients currently receive another investigational drug eligible . Anticancer Agents : patient currently receive anticancer agent eligible . 5 . Patients History Autoimmune Disease : patient history Grade autoimmune disorder eligible . Asymptomatic laboratory abnormality ( e.g . ANA , rheumatoid factor , alter thyroid function study ) render patient ineligible absence diagnosis autoimmune disorder . Patients permit enroll vitiligo , type I diabetes mellitus , psoriasis require systemic treatment , condition expect recur absence external trigger . 6 . Hypothyroidism : patient ≥ Grade 2 hypothyroidism due history autoimmunity eligible . Note : patient residual hypothyroidism due autoimmune condition require hormone replacement , hypothyroidism due previous irradiation thyroidectomy permit . 7 . Infection : patient uncontrolled infection eligible . 8 . HIV and/or Hepatitis B/C Patients : patient know HIV/AIDS acute/chronic hepatitis B C exclude . 9 . Transplant Patients : patient receive prior allogeneic bone marrow transplant prior solid organ transplantation eligible . 10 . NonCompliance : patient opinion investigator may able comply safety monitoring requirement study eligible . 11 . Previous antiPD1 and/or antiPDL1 therapy : Patients receive prior antiPD1 and/or antiPDL1 direct therapy ( mAb small molecule ) eligible</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>